Factor B and protein C2 point mutants, a method of enhancing the activity of anti-cancer antibodies, the pharmaceutical composition and the use of mutants
The subject of the offer is an invention allowing us to enhance the cytotoxic activity of antibody-based drugs used, among others, to fight haematological malignancies. A patent was awarded to this invention in Poland, bearing number Pat.237868 and in the United States with the number USAppl.np.17/045058.
